Humacyte (HUMA) & Its Rivals Head to Head Analysis

Humacyte (NASDAQ:HUMA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Humacyte to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares Humacyte and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Humacyte -3,955.05% -612.88% -80.03%
Humacyte Competitors -12,516.26% -215.37% -31.41%

Volatility & Risk

Humacyte has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Humacyte’s rivals have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.

Institutional and Insider Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Humacyte and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humacyte 1 1 6 0 2.62
Humacyte Competitors 9926 15341 45743 1601 2.54

Humacyte currently has a consensus price target of $4.48, suggesting a potential upside of 726.04%. As a group, “Biotechnology” companies have a potential upside of 110.60%. Given Humacyte’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Humacyte is more favorable than its rivals.

Earnings and Valuation

This table compares Humacyte and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Humacyte $2.04 million -$40.83 million -1.23
Humacyte Competitors $718.90 million $8.79 million -18.37

Humacyte’s rivals have higher revenue and earnings than Humacyte. Humacyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Humacyte rivals beat Humacyte on 7 of the 12 factors compared.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.